Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.3044
+0.0134 (4.60%)
Feb 12, 2026, 1:13 PM EST - Market open

Silo Pharma Statistics

Total Valuation

Silo Pharma has a market cap or net worth of $4.05 million. The enterprise value is -$1.85 million.

Market Cap4.05M
Enterprise Value -1.85M

Important Dates

The next estimated earnings date is Monday, March 30, 2026, after market close.

Earnings Date Mar 30, 2026
Ex-Dividend Date n/a

Share Statistics

Silo Pharma has 13.32 million shares outstanding. The number of shares has increased by 87.67% in one year.

Current Share Class 13.32M
Shares Outstanding 13.32M
Shares Change (YoY) +87.67%
Shares Change (QoQ) +48.59%
Owned by Insiders (%) 10.41%
Owned by Institutions (%) 6.29%
Float 10.28M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 24.86
Forward PS n/a
PB Ratio 0.61
P/TBV Ratio 0.84
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.70

Current Ratio 8.70
Quick Ratio 8.29
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1,088.94

Financial Efficiency

Return on equity (ROE) is -86.11% and return on invested capital (ROIC) is -56.27%.

Return on Equity (ROE) -86.11%
Return on Assets (ROA) -44.37%
Return on Invested Capital (ROIC) -56.27%
Return on Capital Employed (ROCE) -93.50%
Weighted Average Cost of Capital (WACC) 7.65%
Revenue Per Employee $24,034
Profits Per Employee -$1.69M
Employee Count3
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -80.86% in the last 52 weeks. The beta is 0.62, so Silo Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.62
52-Week Price Change -80.86%
50-Day Moving Average 0.38
200-Day Moving Average 0.56
Relative Strength Index (RSI) 35.18
Average Volume (20 Days) 103,544

Short Selling Information

The latest short interest is 67,438, so 0.51% of the outstanding shares have been sold short.

Short Interest 67,438
Short Previous Month 134,766
Short % of Shares Out 0.51%
Short % of Float 0.66%
Short Ratio (days to cover) 3.05

Income Statement

In the last 12 months, Silo Pharma had revenue of $72,102 and -$5.08 million in losses. Loss per share was -$0.82.

Revenue72,102
Gross Profit 47,036
Operating Income -5.31M
Pretax Income -5.08M
Net Income -5.08M
EBITDA -5.30M
EBIT -5.31M
Loss Per Share -$0.82
Full Income Statement

Balance Sheet

The company has $5.87 million in cash and n/a in debt, with a net cash position of $5.87 million or $0.44 per share.

Cash & Cash Equivalents 5.87M
Total Debt n/a
Net Cash 5.87M
Net Cash Per Share $0.44
Equity (Book Value) 5.01M
Book Value Per Share 0.48
Working Capital 5.46M
Full Balance Sheet

Cash Flow

Operating Cash Flow -4.80M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin 65.24%
Operating Margin -7,361.09%
Pretax Margin -7,041.12%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Silo Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -87.67%
Shareholder Yield -87.67%
Earnings Yield -126.39%
FCF Yield n/a

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on September 15, 2022. It was a reverse split with a ratio of 1:50.

Last Split Date Sep 15, 2022
Split Type Reverse
Split Ratio 1:50

Scores

Silo Pharma has an Altman Z-Score of -3.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.48
Piotroski F-Score 3